{"text": ["U.S.", "approves", "Novartis", "cell", "therapy", "for", "lymphoma"], "created_at": "2018-05-01 23:11:45"}
{"text": ["Novartis", "says", "Kymriah", "receives", "second", "U.S.", "FDA", "approval"], "created_at": "2018-05-01 21:35:25"}
{"text": ["Incyte", "(INCY)", "Incurs", "Loss", "in", "Q1,", "Revenues", "Miss", "Estimates"], "created_at": "2018-05-01 21:08:32"}
{"text": ["Incyte", "(INCY)", "Incurs", "Loss", "in", "Q1,", "Revenues", "Miss", "Estimates"], "created_at": "2018-05-01 21:08:32"}
{"text": ["Breakthrough", "cancer", "therapy", "developed", "at", "Penn", "receives", "2nd", "FDA", "approval"], "created_at": "2018-05-01 20:43:34"}
{"text": ["Benzinga's", "Daily", "Biotech", "Pulse:", "Karyopharm's", "STORM", "Study,", "Inogen", "Rallies", "On", "Earnings"], "created_at": "2018-05-01 11:51:51"}
{"text": ["GlaxoSmithKline\u2019s", "Valuation", "after", "1Q18", "Earnings"], "created_at": "2018-05-01 11:30:54"}
{"text": ["Pfizer", "tops", "earnings", "estimates,", "driven", "by", "sales", "of", "pneumonia", "vaccine", "Prevnar"], "created_at": "2018-05-01 10:55:00"}
{"text": ["Novartis", "provides", "update", "on", "proposed", "acquisition", "of", "AveXis"], "created_at": "2018-05-01 05:01:01"}
{"text": ["Novartis-AveXis", "Deal", "Receives", "U.S.", "Regulatory", "Approval"], "created_at": "2018-05-01 01:31:00"}
{"text": ["Novartis-AveXis", "Deal", "Receives", "U.S.", "Regulatory", "Approval"], "created_at": "2018-05-01 01:31:00"}
